|
Scientific Publications:
Bluman LG, Rimer BK, Sterba KR, Lancaster J, Clark S, Borstelmann N, Iglehart
JD, Winer EP: Attitudes, knowledge, risk perceptions and decision-making among
women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2
and their spouses. In press, Psycho-Oncology.
Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM,
Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA,
Younger J, Smith BL, Winer EP: Preoperative therapy with Trastuzumab and Paclitaxel
followed by sequential adjuvant Doxorubicin/Clyclophosphamide for HER2 overexpressing
stage II or III breast cancer. In press, J Clin Oncol.
Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM,
Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA,
Younger J, Smith BL, Winer EP: Preoperative therapy with Trastuzumab and Paclitaxel
followed by sequential adjuvant Doxorubicin/Clyclophosphamide for HER2 overexpressing
stage II or III breast cancer. In press, J Clin Oncol.
Campos S, Winer E: Hormonal therapy in postmenopausal women with breast cancer.
In press, Oncology.
Harris LN, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Wells L, Winer,
EP. Liposome-encapsulated Doxorubicin compared to conventional Doxorubicin in
a randomized multicenter trial as first-line therapy of metastatic breast cancer.
Cancer 2002;94:25-36.
Partridge AH, Avorn J, Wang PS, Winer EP: Adherence to therapy with oral anineoplastic
agents. J Natl Cancer Inst 2002;94(9):652-661.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP: 2002 Update of recommendation
for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines
of the American Society of Clinical Oncology. J Clin Oncol 2002;20(12):2895-2903.
Ligibel JA, Winer EP: Trastuzumab/Chemotherapy combinations in metastatic breast
cancer. Semin Oncol 2002;29(3), Suppl 11:38-43.
Partridge AH, Winer EP: Informing clinical trial participants about study results.
JAMA. 2002;288(3):363-365.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas
EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti
J, Powles TJ, Whelan TJ, Browman GP: American Society of Clinical Oncology technology
assessment on the use of aromatase inhibitors as adjuvant therapy for women with
hormone receptor-positive breast cancer: status report 200. J Clin Oncol 2002
Aug 1;20(15):3317-3327.
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein
HJ, Eisen A, Lipkus I, Pfister DG: American Society of Clinical Oncology technology
assessment of pharmacologic interventions for breast cancer risk reduction including
tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002 Aug 1;20(15):3328-43.
Skinner, CS, Schildkraut J, Berry D, Marcom PK, Sugarman J, Winer EP: Pre-counseling
education materials for BRCA testing: Does tailoring make a difference? Genetic
Testing 2002 6(2):93-105.
Demark-Wahnefried W, Peterson B, Winer EP, Marks LM, Aziz N, Marcom PK, Blackwell
K, Rimer B: Changes in weight, body composition, and factors influencing energy
balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.
J Clin Oncol. 2001;19(9):2381-2389.
Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J,
Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman
LN, Winer EP: Clinical activity of trastuzumab and vinorelbine in women with HER2
overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-27-30.
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH.
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients:
improvements in hemoglobin and quality of life similar to three-times-weekly dosing.
J Clin Oncol. 2001;19(11):2875-2882.
Burstein HJ, Bunnell CA, Winer EP: New cytotoxic agents and schedules for advanced
breast cancer. Sem Onc 2001;28(4):344-358.
Sparano JA, Winer EP: Liposomal anthracyclines for breast cancer. Semin Oncol
2001;Aug;28(4 Suppl 12):32-40.
Bluman L, Borstelmann NA, Iglehart JD, Rimer B, Winer EP: Knowledge, satisfaction,
and perceived cancer risk among women diagnosed with DCIS. J Women's Health 2001;10(6):589-598.
Winer EP, Burstein HJ. New combinations with Herceptin® in metastatic breast
cancer. Oncology 2001;Oct;61 Suppl S2:50-57.
Partridge AH, Bunnell CA, Winer EP: Quality of life issues among women undergoing
high-dose chemotherapy for breast cancer. Breast Disease 2001;14:41-50.
Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined
chemohormonal therapy in women with early stage breast cancer. J Natl Cancer Inst
Monogr 2001;30:135-142.
Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ: A
randomized study comparing standard versus moderately high dose megestrol acetate
for patients with advanced prostate carcinoma: Cancer and Leukemia Group B (CALBG)
Study 9181. Cancer 2000;88:825-834.
Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis
UA, Garber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administered on a weekly
basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
Miron A, Schildkraut JM, Rimer BK, Winer EP, Skinner CS, Futreal PA, Culler
D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD: Testing for hereditary
breast cancer and ovarian cancer in the southestern United States. Ann Surg 2000;231:624-634.
Clark S, Bluman LG, Borstelmann N, Regan K, Winer EP, Rimer, BK, Skinner CS:
Patient motivation, satisfaction, and coping in genetic counseling and testing
for BRCA1 and BRCA2. J Genetic Counseling 2000;9:219-235.
Speice J, Harkness H, Laneri H, Frankel R, Roter D, Kornblith AB, Ahles T,
Winer E, Fleishman S, Luber P, Zevon M, McQuellon R, Trief P, Finkel J, Spira
J, Greenberg D, Rowland J, Holland JC: Involving family members in cancer care:
Focus group considerations of patients and oncological providers. Psycho-Oncology
2000;9(2):101-112.
Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi
H, Isaacs Cl, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman
ME, Hayes DF: Phase II evaluation of thalidomide in patients with metastatic breast
cancer. J Clin Oncol 2000;18:2710-2717.
Burstein HJ, Winer EP. Primary care for breast cancer survivors. N Engl J Med
2000;343:1086-1094.
Carlson RW, Anderson BO, Bensinger W, Cox C, Davidson NE, Edge SB, Farrar WB,
Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver
SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff A: : NCCN Practice
Guidelines for Breast Cancer. Oncology (Huntingt). 2000(Nov);14(11A):33-49.
Goss PE, Winer EP, Tannock IF, Schwartz LH: Randomized Phase III trial comparing
the new potent and selective third-generation aromatase inhibitor vorozole with
megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Onc
1999;17:52-63.
Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes
DF, Winer EP: Inability to escalate vinorelbine dose intensity using a daily x
3 schedule with and without filgrastim in patients with metastatic breast cancer.
Cancer Chemother Pharmacol 1999;43:68-72.
Clark S, Bluman LG, Borstelmann N, Regan K, Winer EP, Rimer BK, Skinner CS:
Patients surviving at least twelve months following high dose chemotherapy with
autologous bone marrow support. Psycho-Oncology 1999;8:167-176.
Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut
J, Winer EP: Attitudes, knowledge and risk perceptions of women with breast and/or
ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Onc 1999;17:1040-1046.
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer
E, Wood WC, Frei E, McIntyre OR, Schilsky RL: Safety and efficacy of using a single
agent or a Phase II agent before instituting standard combination chemotherapy
in previously untreated metastatic breast cancer patients: Reports of a randomized
study - CALGB 8642. J Clin Onc 1999;17:1397-1406.
Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR: Is axillary
lymph node dissection indicated for early-stage breast cancer? A decision analysis.
J Clin Onc 1999;17:1465-1473.
Carlson RW, Anderson BO, Bensinger W, Cox C, Davidson NE, Edge SB, Farrar WB,
Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver
SM, Smith ML, Somlo G, Theriault RL, Winer EP: Update: NCCN practice guidelines
for the treatment of breast cancer. Oncology 1999;13(5A):41-66.
Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar
WJ, Green DM, Langdon RJ, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von
Hoff D, Wasserman TH, Winer EP, Pfister DG: American Society of Clinical Oncology
Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants.
J Clin Onc 1999;17:3333-3355.
Vogel C, O'Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, White R,
McGuirt C: Vinorelbine as first-line chemotherapy for advanced breast cancer in
women 60 years of age or older. Ann Onc 1999;10:397-402.
Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis
UA, Parker LM, Harris LN, Winer EP: Phase I study of Doxil and vinorelbine in
metastatic breast cancer. Ann Onc. 1999;10:1113-1116.
Kantoff PW, Halabi S, Conaway M, Picus J, Kirschner J, Hars V, Trump D, Winer
EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory
prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin
Oncol 1999;17:2506-2513.
Winer E, Lindley C, Hardee M, Sawyer W, Brunatti C, Borstelmann N, Peters W:
Quality of life in patients surviving at least twelve months following high dose
chemotherapy with autologous bone marrow support. Psycho-Oncology 1999;8:167-176.
Lindley C, Vasa S, Sawyer W, Winer E: Quality of life and preferences for
treatment following systemic adjuvant therapy for early stage breast cancer. J
Clin Onc 1998;16:1380-1387.
Rimer BK, Sugarman J, Winer E, Bluman LG, Lerman C: Informed consent for BRCA1
and BRCA2 testing. Breast Disease 1998;10(1,2):99-114.
Thompson TE, McCune JS, Bernard SA, Winer EP, Tremont S, Lindley CM: Cancer
pain survey: Patient-centered issues in control. J Pain Symptom Manage 1998;15:275-284.
Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwater G, Peterson B, Leight G,
Winer EP: Complications of axillary lymph node dissection for carcinoma of the
breast: A report based on a patient survey. Cancer 1998;83:1362-1368.
Frank TS, Manley SA, Olufunmilayo IO, Cummings S, Garber JE, Bernhardt B, Antman
K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley
PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber
B, Strong LC, Rieger P, McClure M, Ward BE, Shattuck-Eidens D, Oliphant A, Skolnick
MH, Thomas A: Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with
family history and ovarian cancer risk. J Clin Onc 1998;16:2417-2425.
Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Schildkraut JM: Overestimation
of hereditary breast cancer risk. Ann Surg 1998;228(3):375-384.
Bunnell CA and Winer EP: Oral 5-FU analogues in the treatment of breast cancer.
Onc 1998;12(10) (supplement):39-43.
Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA,: Testing for the
BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: A decision analysis.
Medical Decision Making 1998;18:365-375.
Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E: Probability of carrying
a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl
Cancer Inst 1997;89:227-238.
Demark-Wahnefried W, Rimer BK, Winer EP: Weight gain in women diagnosed with
breast cancer. J Am Diet Assoc 1997;97:519-526, 529.
Demark-Wahnefried W, Hars V, Conaway M, Havlin K, Rimer B, McElveen G, Winer
E: Reduced rates of metabolism and decreased physical activity in breast cancer
patients receiving adjuvant chemotherapy. Am J Clin Nut 1997;65:1495-1501.
Warmuth MA, Sutton LM, Winer EP: A review of hereditary breast cancer: From
screening to risk factor modification. Am J Med 1997;102:407-415.
Sutton LM, Warmuth MA, Petros WP, Winer EP: Pharmacokinetics and clinical impact
of all-trans retinoic acid in metastatic breast cancer: A phase II trial. Cancer
Chemother Pharmacol 1997;40:335-341.
Tessaro I, Borstelmann N, Regan K, Rimer B, Winer E: Genetic testing for susceptibility
to breast cancer: Findings from women's focus groups. J Women's Health 1997;6:317-327.
Winer, EP: Treatment options for patients with refractory breast cancer. Onc
1996;10(6) (supplement):16-20.
Fee-Fulkerson K, Conaway MR, Winer EP, Fulkerson CC, Rimer BK, Georgiade G:
Factors contributing to patient satisfaction with breast construction using silicone
gel implants. Plast Reconst Surg 1996;97:1420-1426.
Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP: Continuous infusion 5-fluorouracil
as first-line therapy for metastatic breast cancer. J Inf Chemo 1996;6:211-216.
Winer EP, Chu L, Spicer DV: Oral vinorelbine (Navelbine) in the treatment of
advanced breast cancer. Semin Oncol 1995;22(5) (supplement):72-79.
Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B,
Budman D, Bigley J, Hohneker J: Randomized comparison of vinorelbine and melphalan
in anthracycline-refractory advanced breast cancer. 1995;J Clin Onc 13:2567-2574.
Winer EP, Sutton LM: Quality of life after bone marrow transplantation. 1994;Onc
8:19-27.
Winer EP: Quality-of-life research in patients with breast cancer. Cancer 1994;74(1)
(supplement):410-415.
Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA,
Lubejko B, Sartorius SE, Ettinger DS, Donehower RC: Pharmacokinetic, bioavailability,
and feasibility study of oral vinorelbine in patients with solid tumors. 1994;J
Clin Onc 12:1754-1763.
Demark-Wahnefried W, Winer EP, Rimer BK: Weight gain in women receiving adjuvant
chemotherapy for breast cancer. Onc 1994;12:10.
Demark-Wahnefried W, Winer EP, Rimer BK: Why do women gain weight with adjuvant
chemotherapy for breast cancer. J Clin Onc 1993;11:1418-1429.
Peters WP, Ross M, Vredenburgh J, Meisenberg B, Marks LB, Winer E, Kurtzberg
J, Bast RC, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio
D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High dose chemotherapy
and autologous bone marrow support as consolidation after standard dose adjuvant
therapy for high-risk primary breast cancer. 1993;J Clin Onc 11:1132-1143.
Winer EP, Fee-Fulkerson K, Fulkerson CC, Georgiade G, Catoe KE, Brunatti C,
Conaway M, Holmes V, Rimer BK: Silicone controversy: A survey of women with breast
cancer and silicone implants. J Natl Cancer Inst 1993;85:1407-1411.
Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RJ, Crawford J,
Herndon JE, Trump DL: Modulation of O6 alkylguanine-DNA alkyltransferase-mediated
carmustine resistance using streptozotocin: A Phase I trial. Can Res 1992;52:2456-2459.
Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan
VC, Fine RL: High dose oral tamoxifen, a potential multidrug resistance reversal
agent: A Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;23:1811-1816.
Brizel DM, Winer EP, Prosnitz LR, Scott J, Crawford J, Moore JO, Gockerman
JP: Improved survival in advanced Hodgkin's disease with the use of combined modality
therapy. Int J Radiat Oncol Biol Phys 1990;19:535-542.
Rosenberg A, Winer EP, Cadman E: The use of adjuvant chemotherapy for breast
cancer in a community practice. Conn Med 1985;49:281-285.
|
